Literature DB >> 19581910

Systems pathology--taking molecular pathology into a new dimension.

Dana Faratian1, Robert G Clyde, John W Crawford, David J Harrison.   

Abstract

The wealth of morphological, histological, and molecular data from human cancers available to pathologists means that pathology is poised to become a truly quantitative systems science. By measuring morphological parameters such as tumor stage and grade, and by measuring molecular biomarkers such as hormone receptor status, pathologists have sometimes accurately predicted what will happen to a patient's tumor. While 'omic' technologies have seemingly improved prognostication and prediction, some molecular 'signatures' are not useful in clinical practice because of the failure to independently validate these approaches. Many associations between gene 'signatures' and clinical response are correlative rather than mechanistic, and such associations are poor predictors of how cellular biochemical networks will behave in perturbed, diseased cells. Using systems biology, the dynamics of reactions in cells and the behavior between cells can be integrated into models of cancer. The challenge is how to integrate multiple data from the clinic into tractable models using mathematical models and systems biology, and how to make the resultant model sufficiently robust to be of practical use. We discuss the difficulties in using mathematics to model cancer, and review some approaches that may be used to allow systems biology to be successfully applied in the clinic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581910     DOI: 10.1038/nrclinonc.2009.102

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  64 in total

Review 1.  Network biology: understanding the cell's functional organization.

Authors:  Albert-László Barabási; Zoltán N Oltvai
Journal:  Nat Rev Genet       Date:  2004-02       Impact factor: 53.242

Review 2.  Mathematical models of cell cycle regulation.

Authors:  Hendrik Fuss; Werner Dubitzky; C Stephen Downes; Mary Jo Kurth
Journal:  Brief Bioinform       Date:  2005-06       Impact factor: 11.622

3.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

4.  Dynamic proteomics of individual cancer cells in response to a drug.

Authors:  A A Cohen; N Geva-Zatorsky; E Eden; M Frenkel-Morgenstern; I Issaeva; A Sigal; R Milo; C Cohen-Saidon; Y Liron; Z Kam; L Cohen; T Danon; N Perzov; U Alon
Journal:  Science       Date:  2008-11-20       Impact factor: 47.728

5.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Authors:  Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

6.  Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity.

Authors:  B S Hendriks; J Cook; J M Burke; J M Beusmans; D A Lauffenburger; D de Graaf
Journal:  Syst Biol (Stevenage)       Date:  2006-01

7.  Intravital imaging of metastatic behavior through a mammary imaging window.

Authors:  Dmitriy Kedrin; Bojana Gligorijevic; Jeffrey Wyckoff; Vladislav V Verkhusha; John Condeelis; Jeffrey E Segall; Jacco van Rheenen
Journal:  Nat Methods       Date:  2008-11-09       Impact factor: 28.547

8.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

9.  Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades.

Authors:  Nick I Markevich; Jan B Hoek; Boris N Kholodenko
Journal:  J Cell Biol       Date:  2004-01-26       Impact factor: 10.539

10.  Fitting ordinary differential equations to short time course data.

Authors:  Daniel Brewer; Martino Barenco; Robin Callard; Michael Hubank; Jaroslav Stark
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2008-02-28       Impact factor: 4.226

View more
  17 in total

Review 1.  Systems pathology: a critical review.

Authors:  Jose Costa
Journal:  Mol Oncol       Date:  2011-11-27       Impact factor: 6.603

Review 2.  Would Virchow be a systems biologist? A discourse on the philosophy of science with implications for pathological research.

Authors:  Albrecht Stenzinger; Frederick Klauschen; Daniel Wittschieber; Wilko Weichert; Carsten Denkert; Manfred Dietel; Claudio Roller
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

3.  Reconsidering the bio-detection of tolerance in renal transplantation.

Authors:  Faouzi Braza; Jean Paul Soulillou; Sophie Brouard
Journal:  Chimerism       Date:  2013 Jan-Mar

Review 4.  Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Mol Cancer Ther       Date:  2010-11-01       Impact factor: 6.261

5.  The cycling hair follicle as an ideal systems biology research model.

Authors:  Yusur Al-Nuaimi; Gerold Baier; Rachel E B Watson; Cheng-Ming Chuong; Ralf Paus
Journal:  Exp Dermatol       Date:  2010-08       Impact factor: 3.960

Review 6.  What can molecular pathology contribute to the management of renal cell carcinoma?

Authors:  Grant D Stewart; Fiach C O'Mahony; Thomas Powles; Antony C P Riddick; David J Harrison; Dana Faratian
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

7.  Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.

Authors:  Hyunki Kim; Yolanda E Hartman; Guihua Zhai; Thomas K Chung; Melissa L Korb; Timothy M Beasley; Tong Zhou; Eben L Rosenthal
Journal:  J Magn Reson Imaging       Date:  2015-02-20       Impact factor: 4.813

8.  Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.

Authors:  Galina Lebedeva; Anatoly Sorokin; Dana Faratian; Peter Mullen; Alexey Goltsov; Simon P Langdon; David J Harrison; Igor Goryanin
Journal:  Eur J Pharm Sci       Date:  2011-11-09       Impact factor: 4.384

9.  Systems pathology.

Authors:  Dana Faratian
Journal:  Breast Cancer Res       Date:  2010-12-20       Impact factor: 6.466

10.  Open biomedical pluralism: formalising knowledge about breast cancer phenotypes.

Authors:  Aleksandra Sojic; Oliver Kutz
Journal:  J Biomed Semantics       Date:  2012-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.